Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IUGNF - Imugene thrilled as first patients dosed in VAXINIA MAST combination study

IUGNF - Imugene thrilled as first patients dosed in VAXINIA MAST combination study

Imugene Ltd

(NewsDirect)

Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive thecompany’s Phase 1 MAST (metastatic advanced solid tumours) studyevaluating the safety of novel cancer-killing virus CF33-hNIS(VAXINIA) has seen the first patients dosed in the intravenous andintratumoral (IT) cohorts in combination with Pembrolizumab. Overallthe study aims to recruit up to 100 patients across around 10 trialsites in the United States and Australia.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: Imugene Ltd
Stock Symbol: IUGNF
Market: OTC
Menu
IUGNF IUGNF Quote IUGNF Short IUGNF News IUGNF Articles IUGNF Message Board
Get IUGNF Alerts

News, Short Squeeze, Breakout and More Instantly...